(Q39445629)

12 September 2017

title

Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. (English)

1 reference

12 September 2017

1 reference

1 reference

1 reference

1 reference

1 reference

J D Dias

1

1 reference

12 September 2017

O Hemminki

2

1 reference

12 September 2017

I Diaconu

3

1 reference

12 September 2017

M Hirvinen

4

1 reference

12 September 2017

A Bonetti

5

1 reference

12 September 2017

K Guse

6

1 reference

12 September 2017

S Escutenaire

7

1 reference

12 September 2017

A Kanerva

8

1 reference

12 September 2017

S Pesonen

9

1 reference

12 September 2017

A Löskog

10

1 reference

12 September 2017

V Cerullo

11

1 reference

12 September 2017

A Hemminki

12

1 reference

12 September 2017

language of work or name

1 reference

10 November 2011

1 reference

12 September 2017

1 reference

12 September 2017

volume

19

1 reference

12 September 2017

issue

10

1 reference

12 September 2017

page(s)

988-998

1 reference

https://scigraph.springernature.com/pub.10.1038/gt.2011.176

12 September 2017

exact match

0 references

cites work

Cytokines in cancer pathogenesis and cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

Paradoxical roles of the immune system during cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

Molecular basis of T cell inactivation by CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

Modified adenoviruses for cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

Multimodal approach using oncolytic adenovirus, cetuximab, chemotherapy and radiotherapy in HNSCC low passage tumour cell cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

Treatment of prostate cancer with Ad5/3Delta24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

Noninvasive imaging for evaluation of the systemic delivery of capsid-modified adenoviruses in an orthotopic model of advanced lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

Adenovirus virion stability and the viral genome: size matters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

Anti-CTLA4 Antibody Clinical Trials in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

Phase I/II study of ipilimumab for patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

CTLA-4 blockade: therapeutic potential in cancer treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

From cancer immunosurveillance to cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

Global cancer statistics, 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

The anti-tumor activity of anti-CTLA-4 is mediated through its induction of IFN gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

7 January 2021

Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

7 January 2021

Update on adenovirus and its vectors

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

7 January 2021

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

7 January 2021

Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.176

7 January 2021

Identifiers

DOI

10.1038/GT.2011.176

1 reference

12 September 2017

1 reference